环氧合酶-2影响弥漫大B细胞淋巴瘤患者预后相关因素初探
目的探讨环氧合酶-2（cycloxygenase-2,COX-2）对弥漫大B细胞淋巴瘤（diffuse large B-celllymphoma,DLBCL）患者预后的影响及其相关因素。方法根据2008年WHO淋巴造血组织肿瘤分类重新确认47例非特指型DLBCL患者的病理诊断,并区分生发中心型和非生发中心型。采用免疫组化EnVision二步法检测石蜡包埋肿瘤病理组织中COX-2的表达并分析其与患者预后的关系,同时检测标本BCL-2、Ki67以及P-糖蛋白（P-gp）的表达。结果 47例DLBCL患者中生发中心型仅占14.9%（7/47）;11例表达COX-2,阳性率为23.4%,均来自于非生发...
Saved in:
| Published in | 复旦学报（医学版） Vol. 39; no. 3; pp. 243 - 246 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
复旦大学附属金山医院血液科 上海201508%复旦大学附属金山医院血液科 上海201508%复旦大学附属中山医院血液科 上海200032
2012
复旦大学附属中山医院血液科 上海200032 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1672-8467 |
| DOI | 10.3969/j.issn.1672-8467.2012.03.005 |
Cover
| Abstract | 目的探讨环氧合酶-2（cycloxygenase-2,COX-2）对弥漫大B细胞淋巴瘤（diffuse large B-celllymphoma,DLBCL）患者预后的影响及其相关因素。方法根据2008年WHO淋巴造血组织肿瘤分类重新确认47例非特指型DLBCL患者的病理诊断,并区分生发中心型和非生发中心型。采用免疫组化EnVision二步法检测石蜡包埋肿瘤病理组织中COX-2的表达并分析其与患者预后的关系,同时检测标本BCL-2、Ki67以及P-糖蛋白（P-gp）的表达。结果 47例DLBCL患者中生发中心型仅占14.9%（7/47）;11例表达COX-2,阳性率为23.4%,均来自于非生发中心型DLBCL（P=0.133）。COX-2阳性和阴性患者的中位生存时间分别为20个月和46个月;COX-2阳性患者的1年和5年生存率分别为54.55%和21.82%,而COX-2阴性患者则分别为91.43%和39.26%。两组的生存曲线差异具有统计学意义（P=0.028）。COX-2阳性标本中P-gp与BCL-2阳性表达率较COX-2阴性者高（P=0.020;P=0.004）,但Ki67的表达在两组之间无明显差异（P=0.846）。结论本研究提示阳性表达COX-2的非特指型DLBCL患者多为非生发中心来源,预后较差,高表达P-gp与Bcl-2可能是其不良预后的重要影响因素。 |
|---|---|
| AbstractList | R733.4; 目的 探讨环氧合酶-2( cycloxygenase-2,COX-2)对弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者预后的影响及其相关因素.方法 根据2008年WHO淋巴造血组织肿瘤分类重新确认47例非特指型DLBCL患者的病理诊断,并区分生发中心型和非生发中心型.采用免疫组化EnVision二步法检测石蜡包埋肿瘤病理组织中COX-2的表达并分析其与患者预后的关系,同时检测标本BCL-2、Ki67以及P-糖蛋白(P-gp)的表达.结果 47例DLBCL患者中生发中心型仅占14.9％(7/47);11例表达COX-2,阳性率为23.4％,均来自于非生发中心型DLBCL(P=0.133).COX-2阳性和阴性患者的中位生存时间分别为20个月和46个月；COX-2阳性患者的1年和5年生存率分别为54.55％和21.82％,而COX-2阴性患者则分别为91.43％和39.26％.两组的生存曲线差异具有统计学意义(P=0.028).COX-2阳性标本中P-gp与BCL-2阳性表达率较COX-2阴性者高(P=0.020;P=0.004),但Ki67的表达在两组之间无明显差异(P=0.846).结论 本研究提示阳性表达COX-2的非特指型DLBCL患者多为非生发中心来源,预后较差,高表达P-gp与Bcl-2可能是其不良预后的重要影响因素. 目的探讨环氧合酶-2（cycloxygenase-2,COX-2）对弥漫大B细胞淋巴瘤（diffuse large B-celllymphoma,DLBCL）患者预后的影响及其相关因素。方法根据2008年WHO淋巴造血组织肿瘤分类重新确认47例非特指型DLBCL患者的病理诊断,并区分生发中心型和非生发中心型。采用免疫组化EnVision二步法检测石蜡包埋肿瘤病理组织中COX-2的表达并分析其与患者预后的关系,同时检测标本BCL-2、Ki67以及P-糖蛋白（P-gp）的表达。结果 47例DLBCL患者中生发中心型仅占14.9%（7/47）;11例表达COX-2,阳性率为23.4%,均来自于非生发中心型DLBCL（P=0.133）。COX-2阳性和阴性患者的中位生存时间分别为20个月和46个月;COX-2阳性患者的1年和5年生存率分别为54.55%和21.82%,而COX-2阴性患者则分别为91.43%和39.26%。两组的生存曲线差异具有统计学意义（P=0.028）。COX-2阳性标本中P-gp与BCL-2阳性表达率较COX-2阴性者高（P=0.020;P=0.004）,但Ki67的表达在两组之间无明显差异（P=0.846）。结论本研究提示阳性表达COX-2的非特指型DLBCL患者多为非生发中心来源,预后较差,高表达P-gp与Bcl-2可能是其不良预后的重要影响因素。 |
| Author | 化范例 高松 邬扬炯 李莹 王小云 程韵枫 |
| AuthorAffiliation | 复旦大学附属中山医院血液科,上海200032 复旦大学附属金山医院血液科,上海201508 |
| AuthorAffiliation_xml | – name: 复旦大学附属中山医院血液科 上海200032;复旦大学附属金山医院血液科 上海201508%复旦大学附属金山医院血液科 上海201508%复旦大学附属中山医院血液科 上海200032 |
| Author_FL | CHENG Yun-feng GAO Song HUA Fan-li WANG Xiao-yun WU Yang-jiong LI Ying |
| Author_FL_xml | – sequence: 1 fullname: HUA Fan-li – sequence: 2 fullname: GAO Song – sequence: 3 fullname: WU Yang-jiong – sequence: 4 fullname: LI Ying – sequence: 5 fullname: WANG Xiao-yun – sequence: 6 fullname: CHENG Yun-feng |
| Author_xml | – sequence: 1 fullname: 化范例 高松 邬扬炯 李莹 王小云 程韵枫 |
| BookMark | eNo9j01LAkEAhudgkJk_IujSYbeZndnZnWNJXyR08S6zH6NrtZZLpLeoDCFahC6BFGKGhw4VSQbZz5ld_RdtGJ1eeHl4X54FkPKrvgvAMoIqZpStVlQvCHwVUUNTTEINVYNIUyFWIdRTIP3fz4NsEHgWhBrEzMBaGuzG4Uv0OpDt1rT5oWjy-03e3sjxUzR-lv3Bevx1Nbl4iEbXcjSM7_rR-ePkrDntXcp2GHc-ZfNddrrxsCtb91HYWwRzgh8EbvYvM6CwuVHIbSv5va2d3FpesSnUFYwoZAJxTBwhiGkIl-uYO5TrhGGOkGXqjoVt6hKIXZcgzITtMIsQKFzHNinOgJXZ7Cn3BfdLxUr1pOYnh8Wg3Nh36nXr1x7ixD1hl2asXa76pWMvoY9q3iGvNYoEMV2HBsE_d3946g |
| ClassificationCodes | R733.4 |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.3969/j.issn.1672-8467.2012.03.005 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | The prognostic impact of cyclooxygenase-2 in patients with diffuse large B-cell lymphoma |
| DocumentTitle_FL | The prognostic impact of cyclooxygenase-2 in patients with diffuse large B-cell lymphoma |
| EndPage | 246 |
| ExternalDocumentID | shykdxxb201203005 41955074 |
| GrantInformation_xml | – fundername: 上海市金山区科委基金; 上海市科学技术委员会浦江人才计划 funderid: (2010-3-13); (09PJ1402500) |
| GroupedDBID | -05 2B. 2C~ 2RA 5XA 5XF 92F 92I 92L ABDBF ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CQIGP DIK TCJ TGQ U1G U5O W91 ~WA 4A8 93N ACUHS PSX |
| ID | FETCH-LOGICAL-c605-31609f1a34dff487fea53ad6a5493a11b85db3c6e403ee4139fcd9b440fedc863 |
| ISSN | 1672-8467 |
| IngestDate | Thu May 29 04:01:16 EDT 2025 Wed Feb 14 10:46:50 EST 2024 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 3 |
| Keywords | 预后 BCL-2 P-糖蛋白 弥漫大B细胞淋巴瘤 环氧合酶-2 |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c605-31609f1a34dff487fea53ad6a5493a11b85db3c6e403ee4139fcd9b440fedc863 |
| Notes | diffuse large B cell lymphoma; cyclooxygenase-2; prognosis; P-glycoprotein; BCL-2 Objective To investigate the impact of cyclooxygenase-2 on prognosis in patients with diffuse large B-cell lymphoma（DLBCL） and its related factors.Methods The pathological diagnoses of forty-seven cases of DLBCL（not otherwise specified,NOS）were reconfirmed and then were classified into germinal center B cell-like（GCB） type or non-GCB type based on WHO classification of tumors of haematopoietic and lymphoid tissues（4th edition）.Immunohistochemical EnVision method was performed to detect the expression of COX-2 in the paraffin-embedded tissues of DLBCL.The correlation between COX-2 and the prognoses of these patients was analyzed.Also,the expression of BCL-2,P-glycoprotein（P-gp）and Ki67 were detected.Results In all 47 cases,only 7 cases were GCB type（14.9%）.COX-2 was expressed in 11 samples（23.4%）,which were all non-GCB type（P=0.133）.The median survival of COX-2 positive patients was 20 months,while that of COX-2 negative was 46 mo |
| PageCount | 4 |
| ParticipantIDs | wanfang_journals_shykdxxb201203005 chongqing_primary_41955074 |
| PublicationCentury | 2000 |
| PublicationDate | 2012 |
| PublicationDateYYYYMMDD | 2012-01-01 |
| PublicationDate_xml | – year: 2012 text: 2012 |
| PublicationDecade | 2010 |
| PublicationTitle | 复旦学报（医学版） |
| PublicationTitleAlternate | Fudan University Journal of Medical Sciences |
| PublicationTitle_FL | Fudan University Journal of Medical Sciences |
| PublicationYear | 2012 |
| Publisher | 复旦大学附属金山医院血液科 上海201508%复旦大学附属金山医院血液科 上海201508%复旦大学附属中山医院血液科 上海200032 复旦大学附属中山医院血液科 上海200032 |
| Publisher_xml | – name: 复旦大学附属中山医院血液科 上海200032 – name: 复旦大学附属金山医院血液科 上海201508%复旦大学附属金山医院血液科 上海201508%复旦大学附属中山医院血液科 上海200032 |
| SSID | ssib002039732 ssib036437206 ssib051371206 ssj0001844257 ssib002423895 ssib038076145 ssib002805881 ssib006704044 ssib001104042 ssib005319430 |
| Score | 1.9038261 |
| Snippet | 目的探讨环氧合酶-2（cycloxygenase-2,COX-2）对弥漫大B细胞淋巴瘤（diffuse large B-celllymphoma,DLBCL）患者预后的影响及其相关因素。方法根据2008年WHO淋巴造血组织肿... R733.4; 目的 探讨环氧合酶-2( cycloxygenase-2,COX-2)对弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者预后的影响及其相关因素.方法 根据2008年WHO淋巴造... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 243 |
| SubjectTerms | BCL-2 P-糖蛋白 弥漫大B细胞淋巴瘤 环氧合酶-2 预后 |
| Title | 环氧合酶-2影响弥漫大B细胞淋巴瘤患者预后相关因素初探 |
| URI | http://lib.cqvip.com/qk/91097A/201203/41955074.html https://d.wanfangdata.com.cn/periodical/shykdxxb201203005 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals issn: 1672-8467 databaseCode: DIK dateStart: 20080101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: http://www.freemedicaljournals.com omitProxy: true ssIdentifier: ssj0001844257 providerName: Flying Publisher |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1Na9RANLQVxIsoKrZ-UKRzKluTzEdmjpndLNWipwq9LflsQdiqbaH2JGqlIJaCF6EopVZ68KBisYL152S3_Re-eclug0hRL2F47-V9Jpk3H3ljWWOZFzthGEc1ZUcwQEl4VpNuGtVSKjjP0thLcEL_zl0xeY_dnuEzA4ONyq6lpcVoIl75438l_xNVgEFczV-y_xDZPlMAQBviC1eIMFz_KsYk8IgMiN8kgSDaJr5HAk6UTaQkgSKSEy1qroHpBtEOIimRDYTUic_xPmhoA_EZMNCGp9ZEChJIIilRARKBICSChmaGRklzA6CkS3yKxLaRCHJ9l0jW0yRAYk20NBCjEkWUJr6Nshg2uNFZNZAhWORWk-ZSOYlY5RFfIKSBDaD30ZKmsUT5yKpuTDimAeXBG_1NuyWJKkysGysDRnQAJo6j_tpYZ2SB1wIEGSPrKExhw0NIc7ykMlZKc9VqvAxK6S7wQBO5-0Q5iPMl4hRRoDFGAFzs6-r0i1OZi3WEB50JK04T6XUmRWWm8qWh1Z6hqEZVJhluMe_6e_9FlVDYfxkBE30BZgeiW9Ti5cf9dn83JXOUqUrHBq1TrpmVMkODW1PHSTGMuG1WWTu3qSnRVE3SIGutJM3S5tUzBsxXulqjX3iGX_8rTnHp93it3pxgICpr1dyhntPD48ynZKwowds38LQ1Vlp_8yTbTf2Tufn27EPI6vAnu3YWtmcr-eD0OetsOZAb9Yu38rw1sDJ3wZrqrn_qfN7NN9aOVr_V3Pznl_z1q_zgQ-fgY76zq7s_Xhw-e9fZf5nv73Xf7HSevj98snq0_TzfWO9ufs9Xv-abW929rXztbWd9-6I13Qym65O18riSWixwO4mwVeaElCVZxqSXpSGnYSJCzhQNHSeSPIloLFJm0zSF3FFlcaIixuwsTWIp6CVrqD3fTi9bo5DyM09wmjiuwxJPRF6U2jThbgIecVg0bI30_dB6UFSlafWegmHrRumYVvmpWmgtzD2-nywvR8aXtjmgYuQkDlesM4awmGi8ag0tPlpKr0HqvRhdxyfrF1trpC0 |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E7%8E%AF%E6%B0%A7%E5%90%88%E9%85%B6-2%E5%BD%B1%E5%93%8D%E5%BC%A5%E6%BC%AB%E5%A4%A7B%E7%BB%86%E8%83%9E%E6%B7%8B%E5%B7%B4%E7%98%A4%E6%82%A3%E8%80%85%E9%A2%84%E5%90%8E%E7%9B%B8%E5%85%B3%E5%9B%A0%E7%B4%A0%E5%88%9D%E6%8E%A2&rft.jtitle=%E5%A4%8D%E6%97%A6%E5%AD%A6%E6%8A%A5%EF%BC%9A%E5%8C%BB%E5%AD%A6%E7%89%88&rft.au=%E5%8C%96%E8%8C%83%E4%BE%8B+%E9%AB%98%E6%9D%BE+%E9%82%AC%E6%89%AC%E7%82%AF+%E6%9D%8E%E8%8E%B9+%E7%8E%8B%E5%B0%8F%E4%BA%91+%E7%A8%8B%E9%9F%B5%E6%9E%AB&rft.date=2012&rft.issn=1672-8467&rft.volume=39&rft.issue=3&rft.spage=243&rft.epage=246&rft_id=info:doi/10.3969%2Fj.issn.1672-8467.2012.03.005&rft.externalDocID=41955074 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F91097A%2F91097A.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fshykdxxb%2Fshykdxxb.jpg |